PIK3CA and non-small cell lung carcinoma: Activation of the MAPK/ERK pathway following inhibition of PI3K has been observed in a number of cancers [32], including NSCLC [33] and breast cancer [32, 34]; this effect may be mediated through loss of AKT’s inhibitory effect on Raf [35].